About the Company:
AMI Organics is a research and development (“R&D”) driven pharmaceutical intermediate manufacturing company in India
Company is involved in the development of a series of advance pharmaceutical intermediates for the generic and regulated Active Pharmaceutical Ingredients (“APIs”) and New chemical Entity (“NCE”), the synthesis of which is the first step in the process of drug development.
Since Inception in 2004, Company has developed and manufactured approximately two hundred and fifty (250) pharmaceutical intermediates for APIs
Company’s strategic and early investments in research and development (“R&D”) and manufacturing infrastructure have enabled them to become a supplier of pharmaceutical intermediates for APIs in more than seventeen (17) therapeutic areas to multi-national pharmaceutical formulation companies which cater to the large and fast-growing markets of Europe, China, Japan, Israel, UK and the USA.
Company’s pharmaceutical intermediates can be used for approximately more than one hundred (100) APIs, including Apixaban, Vilazodone, Trazodone, Dolutagravir and Entacapone among others.
For Fiscal 2018, Company’s domestic and international operations accounted for 47.00% and 53.00%, respectively, of their revenue from operations.
Some of the key Customers include:
- Organike S.R.L.A. Socio Unico.
- Fermion Oy.
- Glenmark Pharmaceuticals Ltd.
- A.R.Z. Chemicals International Trade Ltd.
- Magle Chamoswed AB.
- Natco Pharma Limited.
Company’s top three (3) customers constituting approximately 47% of their total revenue from operations for Fiscal 2018 with Organike S.R.L.A. Socio Unico and Fermion Oy comprising of 28% and 11% respectively.
Company exports its products to more than twenty (20) countries and has a consolidated customer base of around one hundred and eighty (180) customers worldwide.
Company’s Manufacturing Facilities:
Company’s manufacturing unit is located at Surat, Gujarat spread over an aggregate land area of 11,229 sq. mtrs.
Company has recently expanded their installed capacity and upon the completion of the said expansion project in April 2018, the installed capacity of their production facility increased from 150 MT to 600 MT.
Capacity and Capacity Utilization:
Note: Company’s Annual Installed Capacity was increased from 150 MT/annum to 600 MT/annum in 2018.
- Mr. Girishkumar Limbabhai Chovatia (Designation: Executive Chairman & Whole Time Director)
- Mr. Nareshbhai Ramjibhai Patel (Designation: Managing Director)
- Mr. Chetankumar Chhaganlal Vaghasia (Designation: Whole Time Director)
Positives for the Company:
Positioning in Pharmaceuticals Intermediate Product Segment.
Company is an organized developer and manufacturer of a series of advance pharmaceutical intermediates for the generic APIs and NCE in select high-growth therapeutic areas.
Company is well positioned to capitalize on the market opportunities as a result of their portfolio and scale of operations.
Long-standing Relationships with Domestic and Multi-National Pharmaceutical Companies.
Company has maintained long-standing relationships with domestic and multi-national pharmaceutical companies.
Company’s top five customers have been with them for nearly half a decade and these customers, in aggregate, contributed to approximately sixty per cent (60%) of their total revenue.
Extensive Geographical Reach.
Company supplies their products to more than twenty (20) countries and have long standing relationships with numerous domestic and global pharmaceutical companies for manufacturing and sale of advance pharmaceutical intermediates for the generic APIs and NCE.
Company supply their products to more than one hundred and eighty (180) customers worldwide directly and through their network of distributors in the overseas markets.
Objectives of the Issue:
- Repayment/ prepayment, in full or part, of certain borrowings availed by the Company
- Funding the long term working capital requirements of the Company.
- Capital expenditure for development of a new research & development facility in the vicinity of the manufacturing facility.
- General corporate purposes.
Peer Group Comparison:
There are no comparable listed companies in India engaged substantially in the same line of business as AMI Organics Ltd, hence comparison with industry peers is not applicable.
Financials of the Company: (Consolidated)
|(in Crores)||FY 14||FY 15||FY 16||FY 17||FY 18|
|Issue Opens on||Will be Updated|
|Issue Closes on:.||Will be Updated|
|Issue Price||Will be Updated|
|Minimum Lot||Will be Updated|
|Minimum Investment||Will be Updated|
|Issue Constitutes||Will be Updated|
|Issue Size||Will be Updated|
|Market Cap||Will be Updated|
|Listing at||NSE & BSE|
|Equity Shares Offered||Will be Updated|
|Equity Shares Prior to the Issue||1,05,00,000|
|Equity Shares after the Issue||1,40,00,000|
|Finalization of Basis of Allotment||Will be Updated|
|Initiation of Refunds||Will be Updated|
|Credit of Equity Shares:||Will be Updated|
|Listing Date:||Will be Updated|
Subscription Details: (Will be Updated)
|(Subscription-Category-Wise (no. of times) Till time : 00:00)||Shares Offered||Day-1||Day-2||Day-3|
IPO Valuation Parameters:
|Earnings Per Share (EPS)||Price To Earnings ratio (PE)||Return on Net Worth (RoNW)||Net Asset Value (NAV)|
|Check IPO Allotment Status:|
Link InTime Website (Click on the below Link)
Reviews of Current & Upcoming IPOs:
|Company Contact Info:|
|AMI Organics Ltd
Plot No. 440/4, 5 & 6
Road No. 82/A, G.I.D.C, Sachin
Surat – 394 230 Gujarat, India
Tel.: (+91) 261 2397193
Facsimile: (+91) 261 2398436
|IPO Registrar Info:|
|Link Intime India Private Limited
C-101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai – 400 083, Maharashtra, India
Telephone: +91 22 4918 6200